European Journal of Medical Research | |
Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity | |
PE Manconi2  M Floridia1  LE Weimer1  F Ortu2  | |
[1] Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy;Clinic of Infectious Diseases, Department of Medicine and Immunology, University of Cagliari, Italy | |
关键词: chronic active hepatitis; emtricitabine; tenofovir; raltegravir; antiretroviral treatment; HIV/HCV; | |
Others : 1093331 DOI : 10.1186/2047-783X-15-2-81 |
|
received in 2009-11-26, accepted in 2010-01-21, 发布年份 2010 | |
【 摘 要 】
Background
in HIV-infected patients with HCV-related chronic hepatitis, liver impairment and drug toxicity may substantially reduce the number of possible therapeutic options.
Case Description
we here describe the case of an HCV-HIV coinfected woman who had repeated severe episodes of drug-related liver toxicity with indinavir, saquinavir, fosamprenavir, and darunavir, with minimal further therapeutic options left in this class. Previous treatment-limiting side effects with efavirenz and nevirapine also precluded use of non-nucleoside reverse transcriptase inhibitors. Introduction of an integrase-inhibitor regimen based on raltegravir, tenofovir, and emtricitabine allowed a prompt achievement of undetectable viral load and a substantial rise of CD4 count to high levels, with no subsequent episodes of hepatic toxicity, and no other side effects.
Conclusions
given the relatively common prevalence of HCV-related chronic hepatitis among people with HIV, raltegravir might represent an important alternative option for a substantial number of patients who cannot be treated with protease inhibitors or NNRTI because of drug-related hepatic toxicity.
【 授权许可】
2010 I. Holzapfel Publishers
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
20150130162402412.pdf | 1080KB | download | |
Figure 1. | 92KB | Image | download |
【 图 表 】
Figure 1.
【 参考文献 】
- [1]Singal AK, Anand BS: Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review. World J Gastroenterol 2009, 15:3713-3724.
- [2]Vogel M, Rockstroh JK: Hepatotoxicity and liver disease in the context of HIV therapy. Curr Opin HIV AIDS 2007, 2:306-313.
- [3]Walker UA: Antiretroviral therapy-induced liver alterations. Curr Opin HIV AIDS 2007, 2:293-298.
- [4]Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD: Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004, 18(17):2277-2284.
- [5]Pineda JA, Pérez-Elías MJ, Peña JM, Luque I, Rodríguez-Alcantara F: Fosamprenavir Expanded Access Program Group. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens. HIV Clin Trials 2008, 9:309-313.
- [6]Jevtovic Dj, Ranin J, Salemovic D, et al.: The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART. Biomed Pharmacother 2008, 62:21-25.
- [7]Pineda JA, Santos J, Rivero A, Abdel-Kader L, Palacios R, Camacho A, Lozano F, Macías J, Liverey Study Investigator Team: Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis. J Antimicrob Chemother 2008, 61(4):925-932.
- [8]Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, et al.: Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518. in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007, 369:1261-1269.
- [9]Croxtall JD, Keam SJ: Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients. Drugs 2009, 69:1059-1075.
- [10]Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al.: Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008, 24:339-354.
- [11]Núñez MJ, Martín-Carbonero L, Moreno V, Valencia E, Garcia-Samaniego J, Castillo JG, Barreiro P, González-Lahoz J, Soriano V: Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patients. AIDS Res Hum Retroviruses 2006, 22:825-829.
- [12]Palacios R, Vergara S, Rivero A, Aguilar I, Macías J, Camacho A, Lozano F, García-Lázaro M, Pineda JA, Torre-Cisneros J, Márquez M, Santos J: Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir. HIV Clin Trials 2006, 7:319-323.
- [13]Meraviglia P, Schiavini M, Castagna A, Viganò P, Bini T, Landonio S, Danise A, Moioli MC, Angeli E, Bongiovanni M, Hasson H, Duca P, Cargnel A: Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation. HIV Med 2004, 5:334-343.
- [14]Vispo E, Mena A, Maida I, Blanco F, Cordoba M, Labarga P, et al.: Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2009, in press.